{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T16:45:54Z","timestamp":1781369154923,"version":"3.54.1"},"reference-count":66,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Virtually all neonates with Down syndrome (DS) have hematological abnormalities, including thrombocytopenia, polycythemia, and changes in the types and proportions of leukocytes. While many of these abnormalities are mild, they are important for neonatologists to be aware of, not only because some are life-threatening but also because they affect the interpretation of complete blood cell count results. The most serious hematological condition in neonates with DS is transient abnormal myelopoiesis (TAM), a neonatal leukemic syndrome unique to DS that is caused by mutations in the GATA1 transcription factor gene. In this review, we describe the spectrum of hematological conditions in neonates with DS and their implications, focusing primarily on TAM. We outline the approach to diagnosis and management of these conditions during the neonatal period and their significance for the health of these children in the short and long term. Lastly, we review the nonmalignant hematological abnormalities seen in neonates with DS, which are due to the effects of the extra 21 chromosome in the absence of GATA1 mutations.<\/jats:p>","DOI":"10.1542\/neo.27-1-086","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:03:29Z","timestamp":1767225809000},"page":"e25-e38","source":"Crossref","is-referenced-by-count":1,"title":["Hematological Conditions in Infants With Trisomy 21"],"prefix":"10.1542","volume":"27","author":[{"given":"Neha","family":"Bhatnagar","sequence":"first","affiliation":[{"name":"1Children\u2019s Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom"},{"name":"2Department of Paediatrics, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Children\u2019s Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom"},{"name":"2Department of Paediatrics, University of Oxford, Oxford, United Kingdom"},{"name":"3Department of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Headington, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"issue":"10","key":"2025123119032144200_r1","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/ajmg.a.38402","article-title":"Estimation of live birth and population prevalence of Down syndrome in nine U.S. states","volume":"173","author":"de Graaf","year":"2017","journal-title":"Am J Med Genet A."},{"issue":"3","key":"2025123119032144200_r2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41431-020-00748-y","article-title":"Estimation of the number of people with Down syndrome in Europe","volume":"29","author":"de Graaf","year":"2021","journal-title":"Eur J Hum Genet."},{"issue":"12","key":"2025123119032144200_r3","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.gim.2022.08.029","article-title":"Estimation of the number of people with Down syndrome in Australia and New Zealand","volume":"2 4","author":"de Graaf","year":"2022","journal-title":"Genet Med."},{"issue":"1","key":"2025123119032144200_r4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","article-title":"Down syndrome","volume":"6","author":"Antonarakis","year":"2020","journal-title":"Nat Rev Dis Primers."},{"issue":"5","key":"2025123119032144200_r5","doi-asserted-by":"crossref","first-page":"e2022057010","DOI":"10.1542\/peds.2022-057010","article-title":"Health supervision for children and adolescents with Down syndrome","volume":"149","author":"Bull","year":"2022","journal-title":"Pediatrics."},{"issue":"9199","key":"2025123119032144200_r6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet."},{"issue":"11","key":"2025123119032144200_r7","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2016.23","article-title":"Low risk of solid tumors in persons with Down syndrome","volume":"18","author":"Hasle","year":"2016","journal-title":"Genet Med."},{"issue":"13","key":"2025123119032144200_r8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood.2025029250","article-title":"Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome","volume":"146","author":"Elliot","year":"2025","journal-title":"Blood."},{"key":"2025123119032144200_r9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2021.03.001","article-title":"Leukemia risk in a cohort of 3.9\u00a0million children with and without Down syndrome","volume":"234","author":"Marlow","year":"2021","journal-title":"J Pediatr."},{"issue":"24","key":"2025123119032144200_r10","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2025123119032144200_r11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajmg.a.31442","article-title":"Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system","volume":"143A","author":"Henry","year":"2007","journal-title":"Am J Med Genet A."},{"issue":"5","key":"2025123119032144200_r12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.13096","article-title":"Haematopoietic development and leukaemia in Down syndrome","volume":"167","author":"Roberts","year":"2014","journal-title":"Br J Haematol."},{"issue":"1","key":"2025123119032144200_r13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2022000395","article-title":"Leukemogenesis in infants and young children with trisomy 21","volume":"2022","author":"Roberts","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"7","key":"2025123119032144200_r14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"key":"2025123119032144200_r15","first-page":"29","volume-title":"Paediatric Tumours","author":"Roberts","year":"2023"},{"issue":"6551","key":"2025123119032144200_r16","doi-asserted-by":"crossref","first-page":"eabf6202","DOI":"10.1126\/science.abf6202","article-title":"Mapping the cellular origin and early evolution of leukemia in Down syndrome","volume":"373","author":"Wagenblast","year":"2021","journal-title":"Science."},{"issue":"7","key":"2025123119032144200_r17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/ng1825","article-title":"An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis","volume":"38","author":"Hollanda","year":"2006","journal-title":"Nat Genet."},{"issue":"1","key":"2025123119032144200_r18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcdb.2004.11.002","article-title":"GATA1 in normal and malignant hematopoiesis","volume":"16","author":"Crispino","year":"2005","journal-title":"Semin Cell Dev Biol."},{"issue":"43","key":"2025123119032144200_r19","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1073\/pnas.1211405109","article-title":"Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21","volume":"109","author":"Roy","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2025123119032144200_r20","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1172\/JCI75714","article-title":"Pluripotent stem cells reveal erythroid-specific activities of the GATA1\u00a0N-terminus","volume":"125","author":"Byrska-Bishop","year":"2015","journal-title":"J Clin Invest."},{"issue":"6","key":"2025123119032144200_r21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.celrep.2016.04.031","article-title":"Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities","volume":"15","author":"Banno","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"2025123119032144200_r22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet."},{"issue":"11","key":"2025123119032144200_r23","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood."},{"issue":"3","key":"2025123119032144200_r24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2002-11-3599","article-title":"Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21","volume":"102","author":"Rainis","year":"2003","journal-title":"Blood."},{"issue":"8","key":"2025123119032144200_r25","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2011-03-342774","article-title":"Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia","volume":"118","author":"Alford","year":"2011","journal-title":"Blood."},{"issue":"5","key":"2025123119032144200_r26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3324\/haematol.2014.112714","article-title":"Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression","volume":"100","author":"Chlon","year":"2015","journal-title":"Haematologica."},{"issue":"19","key":"2025123119032144200_r27","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019001234","article-title":"Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1\u00a0N terminus in erythropoiesis","volume":"134","author":"Ling","year":"2019","journal-title":"Blood."},{"issue":"6","key":"2025123119032144200_r28","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","article-title":"Treatment and prognostic impact of transient leukemia in neonates with Down syndrome","volume":"111","author":"Klusmann","year":"2008","journal-title":"Blood."},{"issue":"4","key":"2025123119032144200_r29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2008.07231.x","article-title":"Risk factors for early death in neonates with Down syndrome and transient leukaemia","volume":"142","author":"Muramatsu","year":"2008","journal-title":"Br J Haematol."},{"issue":"26","key":"2025123119032144200_r30","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children\u2019s Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood."},{"issue":"2","key":"2025123119032144200_r31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.15390","article-title":"Guidelines for the investigation and management of transient leukaemia of Down syndrome","volume":"182","author":"Tunstall","year":"2018","journal-title":"Br J Haematol."},{"issue":"1","key":"2025123119032144200_r32","doi-asserted-by":"crossref","first-page":"F67","DOI":"10.1136\/archdischild-2014-308004","article-title":"Prenatal therapy in transient abnormal myelopoiesis: a systematic review","volume":"101","author":"Tamblyn","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"issue":"2","key":"2025123119032144200_r33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12185-013-1487-5","article-title":"Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis","volume":"99","author":"Park","year":"2014","journal-title":"Int J Hematol."},{"issue":"5","key":"2025123119032144200_r34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/pde.13931","article-title":"Neonatal vesiculopustular eruption in Down syndrome and transient myeloproliferative disorder: A case report and review of the literature","volume":"36","author":"Brazzelli","year":"2019","journal-title":"Pediatr Dermatol."},{"issue":"2","key":"2025123119032144200_r35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1440-1754.2011.02407.x","article-title":"Cutaneous lesions in transient abnormal myelopoiesis","volume":"48","author":"Winckworth","year":"2012","journal-title":"J Paediatr Child Health."},{"issue":"4","key":"2025123119032144200_r36","doi-asserted-by":"crossref","first-page":"e251523","DOI":"10.1136\/bcr-2022-251523","article-title":"Bullous eruptions in transient abnormal myelopoiesis with normal phenotype","volume":"16","author":"Shivamallappa","year":"2023","journal-title":"BMJ Case Rep."},{"issue":"10","key":"2025123119032144200_r37","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1365-4632.2012.05501.x","article-title":"Neonatal vesiculopustular eruption associated with transient myeloproliferative disorder: report of four cases","volume":"52","author":"Narvaez-Rosales","year":"2013","journal-title":"Int J Dermatol."},{"issue":"5","key":"2025123119032144200_r38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.0736-8046.2004.21505.x","article-title":"Transient myeloproliferative disorder causing a vesiculopustular eruption in a phenotypically normal neonate","volume":"21","author":"Solky","year":"2004","journal-title":"Pediatr Dermatol."},{"issue":"2 suppl","key":"2025123119032144200_r39","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jaad.2005.08.042","article-title":"Pustular leukemoid reaction in a neonate with Down syndrome","volume":"54","author":"Wirges","year":"2006","journal-title":"J Am Acad Dermatol."},{"issue":"12","key":"2025123119032144200_r40","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2005-06-2448","article-title":"A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children\u2019s Oncology Group (COG) study POG-9481","volume":"107","author":"Massey","year":"2006","journal-title":"Blood."},{"issue":"3","key":"2025123119032144200_r41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/15513819009067127","article-title":"Perinatal visceral fibrosis accompanying the megakaryoblastic leukemoid reaction of Down syndrome","volume":"10","author":"Becroft","year":"1990","journal-title":"Pediatr Pathol."},{"issue":"6","key":"2025123119032144200_r42","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood.V80.6.1521.1521","article-title":"Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down\u2019s syndrome: a report of four autopsy cases and proposal of a hypothesis","volume":"80","author":"Miyauchi","year":"1992","journal-title":"Blood."},{"issue":"3","key":"2025123119032144200_r43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-2005-836510","article-title":"Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts","volume":"217","author":"Langebrake","year":"2005","journal-title":"Klin Padiatr."},{"issue":"6","key":"2025123119032144200_r44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/a-1532-2016","article-title":"Recommendations for diagnosis and treatment of children with transient abnormal myelopoiesis (TAM) and myeloid leukemia in Down syndrome (ML-DS)","volume":"233","author":"Al-Kershi","year":"2021","journal-title":"Klin Padiatr."},{"issue":"8","key":"2025123119032144200_r45","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-021-01128-1","article-title":"Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia","volume":"35","author":"Goemans","year":"2021","journal-title":"Leukemia."},{"issue":"11","key":"2025123119032144200_r46","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet."},{"issue":"25","key":"2025123119032144200_r47","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood.2023022247","article-title":"Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms","volume":"143","author":"Sato","year":"2024","journal-title":"Blood."},{"issue":"12","key":"2025123119032144200_r48","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.2020005610","article-title":"Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome","volume":"136","author":"Cruz Hernandez","year":"2020","journal-title":"Blood."},{"issue":"23","key":"2025123119032144200_r49","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood.V126.23.1311.1311","article-title":"Prospective study of 168 infants with transient abnormal myelopoiesis with Down syndrome: Japan Pediatric Leukemia\/Lymphoma Study Group, TAM-10 Study","volume":"126","author":"Muramatsu","year":"2015","journal-title":"Blood."},{"issue":"13","key":"2025123119032144200_r50","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/bloodadvances.2018018945","article-title":"Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study","volume":"2","author":"Flasinski","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"2025123119032144200_r51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00043426-200201000-00004","article-title":"Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study","volume":"24","author":"Al-Kasim","year":"2002","journal-title":"J Pediatr Hematol Oncol."},{"issue":"4","key":"2025123119032144200_r52","first-page":"1393","article-title":"Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin","volume":"94","author":"Taub","year":"1999","journal-title":"Blood."},{"issue":"1","key":"2025123119032144200_r53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood."},{"issue":"5","key":"2025123119032144200_r54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41375-021-01171-y","article-title":"Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome","volume":"35","author":"Yamato","year":"2021","journal-title":"Leukemia."},{"key":"2025123119032144200_r55","article-title":"Childhood Myeloid Proliferations Associated With Down Syndrome Treatment (PDQ\u00ae)\u2013Health Professional Version","author":"National Cancer Institute","year":"2024"},{"issue":"4","key":"2025123119032144200_r56","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/ped.12586","article-title":"Exchange transfusion in patients with Down syndrome and severe transient leukemia","volume":"57","author":"Hayasaka","year":"2015","journal-title":"Pediatr Int."},{"issue":"2","key":"2025123119032144200_r57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell."},{"issue":"7","key":"2025123119032144200_r58","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood-2003-10-3383","article-title":"Natural history of GATA1 mutations in Down syndrome","volume":"103","author":"Ahmed","year":"2004","journal-title":"Blood."},{"issue":"5","key":"2025123119032144200_r59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1469-0705.2001.00384.x","article-title":"Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21","volume":"17","author":"Smrcek","year":"2001","journal-title":"Ultrasound Obstet Gynecol."},{"issue":"3","key":"2025123119032144200_r60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000284928","article-title":"Transient abnormal myelopoiesis associated with Down syndrome presenting as severe hydrops fetalis: a case report","volume":"27","author":"Malin","year":"2010","journal-title":"Fetal Diagn Ther."},{"issue":"4","key":"2025123119032144200_r61","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0022-3476(05)81149-7","article-title":"Erythrocyte macrocytosis in infants and children with Down syndrome","volume":"121","author":"Starc","year":"1992","journal-title":"J Pediatr."},{"issue":"1","key":"2025123119032144200_r62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1399-0004.1996.tb04318.x","article-title":"Peripheral blood cell counts in infants with Down\u2019s syndrome","volume":"49","author":"Kivivuori","year":"1996","journal-title":"Clin Genet."},{"issue":"6","key":"2025123119032144200_r63","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jpeds.2005.07.022","article-title":"Intrinsic abnormalities of lymphocyte counts in children with Down syndrome","volume":"147","author":"de Hingh","year":"2005","journal-title":"J Pediatr."},{"issue":"6","key":"2025123119032144200_r64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jpeds.2005.09.002","article-title":"Down syndrome: immunologic and epidemiologic associations-enigmas remain","volume":"147","author":"Douglas","year":"2005","journal-title":"J Pediatr."},{"issue":"5","key":"2025123119032144200_r65","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1203\/PDR.0b013e3181d4ecc1","article-title":"Down syndrome B-lymphocyte subpopulations, intrinsic defect or decreased T-lymphocyte help","volume":"67","author":"Verstegen","year":"2010","journal-title":"Pediatr Res."},{"issue":"9","key":"2025123119032144200_r66","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/leu.2016.164","article-title":"The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome","volume":"30","author":"Lee","year":"2016","journal-title":"Leukemia."}],"container-title":["NeoReviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/27\/1\/e25\/1905168\/neoreviews.062025cmerev00105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/27\/1\/e25\/1905168\/neoreviews.062025cmerev00105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:03:35Z","timestamp":1767225815000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/neoreviews\/article\/27\/1\/e25\/206030\/Hematological-Conditions-in-Infants-With-Trisomy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/neo.27-1-086","relation":{},"ISSN":["1526-9906"],"issn-type":[{"value":"1526-9906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}